Something went wrong with the connection!

Boisenews Now

Duchenne Muscular Dystrophy Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – Sarepta, Pfizer, Italfarmaco, FibroGen, Mitobridge

 Breaking News
  • No posts were found

Duchenne Muscular Dystrophy Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – Sarepta, Pfizer, Italfarmaco, FibroGen, Mitobridge

March 01
23:38 2023
Duchenne Muscular Dystrophy Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies - Sarepta, Pfizer, Italfarmaco, FibroGen, Mitobridge
Delveinsight Business Research LLP
As per DelveInsight, the Duchenne Muscular Dystrophy Market is anticipated to grow in the coming years owing to the rising awareness of the disease, incremental healthcare spending across the world, and the rise in the number of cases.

The companies and academics are working to assess challenges and seek opportunities that could influence Duchenne Muscular Dystrophy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition. Major players such as Sarepta Therapeutics, Pfizer, Santhera Pharmaceuticals, Taiho Pharmaceuticals, and others are involved in developing therapies for Duchenne Muscular Dystrophy. The launch of emerging therapies will significantly impact the Duchenne Muscular Dystrophy market.

DelveInsight’s “Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Duchenne Muscular Dystrophy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Duchenne Muscular Dystrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Duchenne Muscular Dystrophy Market

Duchenne Muscular Dystrophy: An Overview

Duchenne Muscular Dystrophy is a progressive form of muscular dystrophy that occurs primarily in males, though in rare cases may affect females. DMD causes progressive weakness and loss (atrophy) of skeletal and heart muscles,

DMD is caused by an absence of dystrophin, a protein that helps keep muscle cells intact. Symptom onset is in early childhood, usually between ages 3–5. The disease primarily affects boys, but in rare cases, it can affect girls. DMD is inherited as an X-linked disease. X-linked genetic disorders are conditions caused by an abnormal gene on the X chromosome and manifest mostly in males. Females with a defective gene on one of their X chromosomes are carriers for that disorder.

According to the National Institute of Health, US. Duchenne Muscular Dystrophy is a rare muscle disorder, but it is one of the most frequent genetic conditions, affecting approximately 1 in 3,500 male births worldwide. It is usually recognized between three and six years of age.

Duchenne Muscular Dystrophy Market Key Facts

  • The market size of Duchenne Muscular Dystrophy in the seven major markets was USD 745.4 Million in 2020.

  • The United States accounts for the largest market size of Duchenne Muscular Dystrophy in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

  • The United States accounted for the largest market size of DMD, USD 623.7 Million in 2020, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

  • Japan accounted for USD 22.7 Million in 2020, which is expected to rise during the forecast period.

  • The total prevalent population of Duchene muscular dystrophy (DMD) in the 7MM was found to be 30,688 in 2020. 

  • Epidemiology assessed for DMD showed that the US, in 2020, accounted for approximately 16,765 prevalent cases of DMD.

  • In the United States, the maximum number of DMD patients affected was 3,185 with Attention-deficit hyperactivity disorder (ADHD), followed by 3,353 with Scoliosis cases, 2,515 with Cardiomyopathy cases, 2,180 with Obsessive-compulsive disorder (OCD) cases in 2020, and several other comorbidities.

  • Among the EU-5 countries in 2020, the UK had the highest prevalent population of DMD patients, with 2,622 cases, followed by Germany (2,596) and France (2,101). In contrast, Spain had the lowest cases (1,478) in 2020.

  • In the United States, in 2020, the highest proportion of age-specific cases was observed in 5–9 years, followed by age groups of 10–14 years and 15–20 years.

  • In Japan, 2,571 large mutation and 643 small mutation cases were observed in 2020.

Duchenne Muscular Dystrophy Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Duchenne Muscular Dystrophy market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Duchenne Muscular Dystrophy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Duchenne Muscular Dystrophy Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Duchenne Muscular Dystrophy Epidemiology, Segmented as –

  • Total Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the 7MM [2019-2032]

  • Age-specific Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the 7MM [2019-2032]

  • Associated Comorbidities in Duchenne Muscular Dystrophy (DMD) in the 7MM [2019-2032]

  • Mutation-specific Prevalent Population of Duchenne Muscular Dystrophy (DMD) in the 7MM [2019-2032]

  • Ambulatory and non-ambulatory Population of Duchenne Muscular Dystrophy (DMD) in the 7MM [2019-2032]

Duchenne Muscular Dystrophy Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Duchenne Muscular Dystrophy market or expected to be launched during the study period. The analysis covers the Duchenne Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Duchenne Muscular Dystrophy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Duchenne Muscular Dystrophy Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market

Leading Companies in the Duchenne Muscular Dystrophy Therapeutics Market Include:

  • Antisense Therapeutics

  • Bioleaders Corporation

  • Capricor

  • Daiichi Sankyo

  • FibroGen

  • Italfarmaco

  • Mitobridge

  • Nippon Shinyaku

  • Pfizer

  • PTC Therapeutics

  • ReveraGen BioPharma

  • Santhera Pharmaceuticals

  • Sarepta Therapeutics

  • Solid Biosciences

  • Taiho Pharmaceutical

  • Vertex Pharmaceuticals

  • WaVe life Sciences

And Many Others 

Duchenne Muscular Dystrophy Marketed and Emerging Therapies Covered in the Report Include

  • Vyondys 53 (Golodirsen): Sarepta Therapeutics

  • Emflaza: PTC Therapeutics

  • Exondys 51: Sarepta Therapeutics

  • Translarna: PTC Therapeutics

  • Amondys 45: Sarepta Therapeutics

  • Viltepso: Nippon Shinyaku

  • PF-06939926: Pfizer

  • Vamorolone: Santhera Pharmaceuticals/ReveraGen BioPharma

  • Pizuglanstat (TAS-205): Taiho Pharmaceutical

  • Givinostat: Italfarmaco

  • CRISPR/Cas9 gene editing therapy: Vertex Pharmaceuticals

  • WVE N531: WaVe life Sciences

  • Pamrevlumab: FibroGen

  • TAS-205: Taiho Pharmaceutical

  • MA-0211: Mitobridge

  • BLS-M22: Bioleaders Corporation

  • CAP 1002: Capricor

  • DS-5141: Daiichi Sankyo

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Duchenne Muscular Dystrophy Competitive Intelligence Analysis

4. Duchenne Muscular Dystrophy Market Overview at a Glance

5. Duchenne Muscular Dystrophy Disease Background and Overview

6. Duchenne Muscular Dystrophy Patient Journey

7. Duchenne Muscular Dystrophy Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Duchenne Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Duchenne Muscular Dystrophy Unmet Needs

10. Key Endpoints of Duchenne Muscular Dystrophy Treatment

11. Duchenne Muscular Dystrophy Marketed Products

12. Duchenne Muscular Dystrophy Emerging Drugs and Latest Therapeutic Advances

13. Duchenne Muscular Dystrophy Seven Major Market Analysis

14. Attribute Analysis

15. Duchenne Muscular Dystrophy Market Outlook (In US, EU5, and Japan)

16. Duchenne Muscular Dystrophy Access and Reimbursement Overview

17. KOL Views on the Duchenne Muscular Dystrophy Market

18. Duchenne Muscular Dystrophy Market Drivers

19. Duchenne Muscular Dystrophy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market

 

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Strategies

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Categories